Inflammation biomarkers capacity in predicting the metabolic syndrome;Capacidade dos biomarcadores inflamatórios em predizer a síndrome metabólica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 3, 2008, Pages 537-549

  Volp, Ana Carolina Pinheiro ^a   Alfenas, Rita De Cássia G ^b   Costa, Neuza Maria Brunoro ^b   Minim, Valéria Paula Rodrigues ^a   Stringueta, Paulo César ^a   Bressan, Josefina ^b  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b UFV

Author keywords

Cytokines; Inflammation; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; FIBRINOGEN; SERUM AMYLOID A;

HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; OBESITY; PHYSIOLOGY; PREDICTION AND FORECASTING; REVIEW;

ADIPOKINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINES; CYTOKINES; FIBRINOGEN; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PREDICTIVE VALUE OF TESTS; SERUM AMYLOID A PROTEIN;

EID: 44949219405     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000300015     Document Type: Review

References (50)

1. Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. Rev Paul Med. 2001;119(3):122-7.
2. Schmidt MI, Duncan BB, Watson RL, Shannett AR, Blancati FL, Heiss G. A metabolic syndrome in whites and african-americans: the atherosclerosis risk in communities (ARIC) baseline study. Diabetes Care. 1996;19(5):414-8.
3. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106: 3143-421.
4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI). Scientific statement. Circulation. 2005;112: 2735-52.
5. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. (IDF 2005)- 7p. Disponível em: hiperlink http://www. idf. org/ webdata/docs/IDF_Metasyndrome_definition.pdf (acesso em 6 out 2007).
6. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effects of insulin: relevance to cardiovascular disease. Am J Cardiol. 2007;99(Suppl):15B-26.
7. Festa A, D'agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42-7.
8. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Cir Res. 2001;89:644-71.
9. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. Circulation. 2003;107:499-511.
10. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, MaCGovern Pg. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the atherosclerosis risk in communities (ARIC) study. Ann Intern Med. 2000;133(2)81-91.
11. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, Di Minno G, Margaglione M, et al. The hifmech study group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the hifmech study. Metabolism. 2004;53:852-7.
12. Kon KK, Han SH, Quon MJ. Inflammatory markers and metabolic syndrome. J Am Coll Cardiol. 2005;46(11):1978-85.
13. Pérez AE. Biología de la pared vascular y síndrome metabólico. Nutr Hosp. 2005;20(1): 5-17.
14. Francisco G, Hernández C, Simó R. Serum markers of vascular inflammation in dyslipidemia. Clin Chim Acta. 2006;369:1-16.
15. Darvall KAL, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007;33:223-33.
16. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
17. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:2-10.
18. Klein J, Perwitz, Kraus D, Fasshauer M. Adipose tissue as source and target for novel therapies. Trends Endocrinol Metab. 2006;17(1):1-7.
19. Wu JT, Wu LL. Linking inflamation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta. 2006;366:74-80.
20. Vanhala PT, Vanhala MJ, Kumpusalo EA, Takala JK. Predictive value of different types of obesity on onset of metabolic syndrome; 5-years follow-up study. XIV International Symposium on Atherosclerosis. Rome, Italy. June 2006 (P453).
21. Rexrode KM, Pradhan A, Mansos JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003;13:1-9.
22. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endotelial dysfunction: a potencial role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.
23. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in pacients with chronic heart failure. Circulation. 2000;102:3060-7.
24. Hung J, McQuillan BM, Chapman CML, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:1268-73.
25. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot -related gene expression in human subcutaneous and omental adipocytes. Diabetes. 1998;47:1384-90.
26. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alfa. Cytokine Growth Factor Rev. 2003;14:447-55.
27. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 1995;27(7):435-8.
28. Winkler G, Kiss S, Ketszthelyi L, Sapi Z, Ory I, Salamon F, et al. Expression of tumor necrosis factor (TNF-alfa) protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alfa, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003;149(2):129-35.
29. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated and cardiovascular disease. Am J Cardiol. 2003;92:3-9.
30. Berrahmoune H, Lamont JV, Herbeth B, Fitzgerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the Stanislas Cohort. Clin Chem. 2006;52:504-10.
31. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119:79-84.
32. Angélico F, Alessandri C, Ferro D, Pignatelli P, Del Ben S, Fiorello S, et al. Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thombin generation. Diabetologia. 2006;49:1169-74.
33. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75:235-40.
34. Suzuki GS, Montes PH, Santomauro AT, Souto RP, Folho FF. Adiponectina é um promissor marcador precoce da síndrome metabólica. Diabetes Clínica. 2005;6:419-27.
35. Monhan V, Deepa R, Pradeepa R, Santhanakrishnan Vimaleswaran K, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome - The Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism. 2005;54(4):476-81.
36. Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007;20:1-5.
37. Ridker PM, Willerson JT. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(2):2-10.
38. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
39. Wilson PWF, Dagostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
40. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy-II PF, Kullo IJ. Association of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypert. 2007;20:83-9.
41. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clin Sci. 2006;61(5):433-40.
42. Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kajii E. Metabolic syndrome and C-reactive protein in the general population-JMS Cohort Study. Circulation. 2007;71:26-31.
43. Browning LM, Jebb SA, Mishra GD, Cooke JH, O'Connell MA, Crook MA, et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Inter J Obes. 2004;28:1004-10(a).
44. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolisis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152:897-907.
45. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Affenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (ARIC study): a cohort study. Lancet. 1999;353:1649-52.
46. Festa A, D'agostino R, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The insulin resistance atherosclerosis study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:562-8.
47. Wu TL, Tsai C, Chang PY, Tsao KC, Sun CF, Wu LL, et al. Establishment of an in-house Elisa and the reference range for serum amyloid A (SAA). Complementary between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta. 2007;376:72-6.
48. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: Nhanes III. Am J Hyp. 2003;16:952-8.
49. Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. J Diabetes Complications. 2006;20: 343-8.
50. Volp ACP, Hermsdorff HHM, Bressan J. Efecto de dietas ricas en sacarosa y en lípidos ingeridas en condiciones de vida libre sobre la resistencia insulínica en mujeres con peso normal y exceso de peso. Nutr Hosp. 2007;22(1):46-60.